Trevena reports positive results of TRV027 proof-of-concept trial in Covid-19 patients

TRV027 is being evaluated as a potential therapy for treating acute lung injury that leads to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients suffering from Covid-19. Credit: Gerd Altmann from Pixabay.